Browse everything: Tickers A–Z · Issuers · Comparisons · Tags
CBIO Stock — Crescent Biopharma, Inc.
Crescent Biopharma, Inc. (CBIO)
Updated October 16, 2026.
CBIO is a Stock. Total return is -98.6% over the past 12.8 years, 511.5 points behind SPY at 412.9%.
Crescent Biopharma is a biotechnology company developing cancer therapy candidates, with a lead program (CR-001) in Phase 3 clinical trials for solid tumors and a strategic partnership with Sichuan Kelun-Biotech for oncology drug development. The company does not currently distribute to shareholders. This security appeals to investors seeking exposure to clinical-stage biopharmaceutical development rather than current income.
CBIO dividend yield and income
Price as of 2026-10-16.
The ex-dividend date is 01/13/2023.
| Ex-date | As paid | Per current share | Change from previous payment |
|---|---|---|---|
| 2023-01-13 | $0.24 | $24 | -83.2% Unclassified cash |
| 2022-09-21 | $1.43 | $143 | — |
| 2022 total | — | $143 | — |
| 2023 total | — | $24 | -83.2% |
CBIO performance versus SPY
Price and return data through 2026-10-16.
Total return is -98.6% over the past 12.8 years, 511.5 points behind SPY at 412.9%. Over the past year its total return — price change plus distributions reinvested — is -4.1%. Its deepest 1-year drawdown was 56.1%.
| Window | Total return | CAGR |
|---|---|---|
| 1M | -31.1% | — |
| 3M | -21.6% | — |
| 6M | -39.1% | — |
| YTD | -0.2% | — |
| 1Y | -4.1% | — |
| 2Y CAGR | — | -14.00% |
| 3Y CAGR | — | -56.40% |
| 5Y CAGR | — | -42.10% |
| 10Y CAGR | — | -31.80% |
| Since inception (12.8 years) | -98.6% | -28.30% |
CBIO key facts
- Asset type
- Stock
- Asset class
- Equity
- Inception date
- 01/10/2014
- Distribution frequency
- None
- Last close
- $11.84 (as of 2026-10-16)
- Market cap
- $439,784,250
- Average volume
- 208151.0
- Ex-dividend date
- 01/13/2023
- Payout ratio
- 0.0%
- EPS
- $-7.63
How Dividend Vision calculates yield and returns
Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.
Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology
Sources and review
Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.
Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.
CBIO risks and drawbacks
Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 56.1%.
Who may consider CBIO — and who may not
It is a weaker fit for investors who need monthly cash flow (CBIO does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.
More on CBIO
Frequently asked questions
Does CBIO pay monthly?
No. CBIO does not currently distribute.
When does CBIO pay a dividend?
CBIO does not currently distribute. The ex-dividend date is 01/13/2023.
How has CBIO performed?
Total return is -98.6% over the past 12.8 years, 511.5 points behind SPY at 412.9%. Over the past year its total return — price change plus distributions reinvested — is -4.1%. Its deepest 1-year drawdown was 56.1%.
Tickers
Holdings as-of date unavailable.
| Ticker | Name | Weight |
|---|
See how this investment would fit into your portfolio.